SoftMedx Healthcare Limited reported interim results for the six months ended 30 June 2026 showing resilient top-line performance and a sharper focus on cost control.

Revenue held broadly steady at HK$34.08 million (2025: HK$35.77 million). Gross profit slipped to HK$9.43 million, and gross margin narrowed to 27.7% from 32.1% as product mix shifted toward lower-margin items.

Administrative expenses fell 20.8% year on year to HK$3.61 million, reflecting tighter cost management and the absence of last year’s legal and professional fees. The Group also avoided the HK$2.82 million fair-value loss recorded in 2025 after exiting listed equity investments.

Driven by these savings, profit attributable to shareholders rose 38.6% to HK$4.65 million (2025: HK$3.35 million). Earnings per share were HK4.4 cents on a post-consolidation weighted average share count of 106.71 million.

Cash flow and leverage improved markedly. Operating activities generated HK$15.20 million (2025: HK$1.68 million), supporting a period-end cash balance of HK$26.51 million—more than double the level at end-2025. All bank borrowings were repaid, moving the Group into a net-cash position and lifting the liquidity ratio to 2.50 from 2.30. Net assets increased to HK$32.22 million, up 17.5% since December 2025.

During the half-year, the Company issued 815,092 new shares at HK$0.20 per share to scheme creditors and completed a 20-for-1 share consolidation. Total issued shares stood at 107.12 million and share capital at HK$3.05 billion as of 30 June 2026.

Management highlighted continued investments in expanding product sources and offerings, leveraging Hong Kong’s growing medical device market and new sales channels in the Greater Bay Area, while maintaining “disciplined execution of prudent financial, liquidity and cash-flow management.”